Systemic Amyloidosis Therapeutic Market Report 2026

The systemic amyloidosis therapeutic market size has grown strongly in recent years. It will grow from $5.67 billion in 2025 to $6.2 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to historical underdiagnosis of amyloidosis, reliance on chemotherapy regimens, growth in hematology treatment centers, increased rare disease awareness, early proteasome inhibitor adoption.

The systemic amyloidosis therapeutic market size is expected to see strong growth in the next few years. It will grow to $8.88 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to rising rare disease diagnosis rates, expansion of targeted biologic drugs, growing gene silencing therapy approvals, increased specialty clinic networks, stronger orphan drug incentives. Major trends in the forecast period include targeted amyloid protein stabilizer drugs, gene silencing amyloidosis therapies, monoclonal antibody based treatments, combination regimen treatment protocols, organ specific supportive drug strategies.

The growing adoption of personalized medicine approaches is anticipated to drive the growth of the systemic amyloidosis therapeutic market in the coming years. Personalized medicine refers to a medical approach that customizes treatment and prevention strategies based on an individual’s genetic profile, biomarkers, and unique disease characteristics. The demand for personalized medicine is rising due to advances in genomic and biomarker technologies, which allow clinicians to precisely identify disease drivers and tailor treatments, improving efficacy and reducing adverse effects for individual patients. The adoption of personalized medicine increases demand for systemic amyloidosis therapeutics as patients with systemic amyloidosis have different amyloid subtypes (e.g., AL, ATTR) and genetic variations, so effective treatment requires therapies specifically designed to target the patient’s unique disease profile, ensuring maximum efficacy and minimal side effects. For example, in April 2025, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit advocacy and educational organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the growing adoption of personalized medicine approaches is driving the growth of the systemic amyloidosis therapeutic market.

Companies operating in the systemic amyloidosis therapeutic market are focusing on developing advanced targeted treatment approaches, such as RNA interference-based therapies, to address the underlying genetic causes of protein misfolding disorders, reduce disease progression, and improve long-term patient outcomes. RNA interference-based therapies work by selectively silencing disease-causing genes, thereby reducing the production of harmful proteins responsible for systemic organ damage. For example, in March 2025, Alnylam Pharmaceuticals, a US-based biotechnology company, launched AMVUTTRA, a targeted, disease-modifying treatment for adults with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). AMVUTTRA works by rapidly suppressing transthyretin production at the source, addressing the underlying cause of amyloid deposition. It demonstrates consistent benefits across cardiovascular outcomes, functional capacity, and quality of life.

In April 2025, Neurimmune, a Switzerland-based clinical-stage biopharmaceutical company focused on next-generation therapeutics for protein aggregation diseases, partnered with Alexion, AstraZeneca Rare Disease to develop and commercialize NI009 for light chain (AL) amyloidosis. Through this partnership, Neurimmune and Alexion aim to accelerate the development of a fibril-depleting monoclonal antibody therapy designed to target and remove lambda light chain amyloid deposits in patients with systemic AL amyloidosis. Alexion is a US-based global biopharmaceutical company specializing in late-stage development, manufacturing, and commercialization of therapies for serious systemic disorders, including amyloidosis.

Major companies operating in the systemic amyloidosis therapeutic market are Johnson & Johnson Services Inc., Sanofi SA, Novartis Plc, AstraZeneca Plc, GSK Plc, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals, Arcturus Therapeutics Inc, Prothena Biosciences, Fortress Biotech Inc., Intellia Therapeutics Inc., Zentalis Pharmaceuticals Inc., BridgeBio Pharma Inc., Neurimmune AG, HaemaLogix Pty Ltd., Attralus Inc., and Oncopeptides AB.

Tariffs on specialty pharmaceuticals, biologic inputs, and injectable drug components are increasing treatment costs in the systemic amyloidosis therapeutic market. Import duties on biologic drug substances and advanced formulation materials are affecting monoclonal antibody and gene based therapy segments. Regions dependent on imported specialty drugs are facing higher therapy pricing. Hospitals and specialty pharmacies are adjusting procurement strategies. Manufacturers are expanding regional fill finish and packaging operations. Some tariffs are encouraging local rare disease drug manufacturing. This is gradually improving regional supply security and production capability.

The systemic amyloidosis therapeutic market research report is one of a series of new reports that provides systemic amyloidosis therapeutic market statistics, including systemic amyloidosis therapeutic industry global market size, regional shares, competitors with a systemic amyloidosis therapeutic market share, detailed systemic amyloidosis therapeutic market segments, market trends and opportunities, and any further data you may need to thrive in the systemic amyloidosis therapeutic industry. This systemic amyloidosis therapeutic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Systemic amyloidosis therapeutics include pharmaceutical and biological treatments designed to manage, slow, or treat systemic amyloidosis, a disorder caused by abnormal buildup of amyloid proteins in organs and tissues across the body. These therapies aim to lower amyloid production, stabilize misfolded proteins, or support organ health to reduce symptoms and improve patient outcomes. It helps limit amyloid accumulation, protect organ function, and enhance survival rates and quality of life for affected patients.

The primary product types of systemic amyloidosis therapeutics include small molecule drugs, biologic therapies, monoclonal antibodies, chemotherapy-based regimens, targeted therapies, and supportive treatments. Small molecule drugs are low molecular weight compounds developed to act on specific biological pathways associated with amyloidosis, thereby limiting amyloid protein accumulation. These therapeutics are offered in formulations such as tablets, capsules, and injections, and are administered through oral, intravenous, or subcutaneous routes. They are distributed via hospital pharmacies, retail pharmacies, and online pharmacies, and are used by end users including hospitals, specialty clinics, specialty pharmacies, research and academic institutes, and other end users.

The systemic amyloidosis therapeutic market consists of sales of immunomodulatory drugs, proteasome inhibitors, alkylating agents, autophagy-modulating agents, cardiac supportive drugs, renal protective medications, and adjunctive symptomatic therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or developers of the therapeutics, whether to other entities (including wholesalers, distributors, hospitals, specialty pharmacies, and healthcare providers) or directly to end users. The value of goods in this market includes related services sold by the creators of the therapeutics.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.